Autolus Therapeutics Plc (AUTL)
1.63
+0.04
(+2.52%)
USD |
NASDAQ |
May 15, 16:00
1.60
-0.03
(-1.84%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 433.81M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 26.36% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 4.681 |
| Price to Book Value | 5.318 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 3.392 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 96.58% |
Profile
| Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom. |
| URL | http://www.autolus.com |
| Investor Relations URL | https://www.autolus.com/investor-relations-media/ |
| HQ State/Province | Greater London |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 14, 2026 (est.) |
| Last Earnings Release | May. 14, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom. |
| URL | http://www.autolus.com |
| Investor Relations URL | https://www.autolus.com/investor-relations-media/ |
| HQ State/Province | Greater London |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 14, 2026 (est.) |
| Last Earnings Release | May. 14, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |